Satellite Symposia webcasts

BREAST CANCER

Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
F. Hoffmann-La Roche

• The biology of breast cancer: Lessons from the past
  Sandra Swain, Washington, United States
• Raising the bar in early TNBC
  Peter Schmid, London, United Kingdom
• Insights from the clinic: Hypothetical eTNBC Patient Scenario(s)
  Carlos Barrios, Porto Alegre, Brazil
• New frontiers in metastatic TNBC
  Rebecca Dent, Singapore, Singapore
• Insights from the clinic: Hypothetical mTNBC Patient Scenario(s)
  Carlos Barrios, Porto Alegre, Brazil
• Looking at the future horizon
  Sandra Swain, Washington, United States
• Live Q&A
  Sandra Swain, Washington, United States, Peter Schmid, London, United Kingdom, Carlos Barrios, Porto Alegre, Brazil, Rebecca Dent, Singapore, Singapore

HER tomorrow in HER2+ metastatic breast cancer
AstraZeneca

• Welcome and introductions
  Eva Ciruelos, Madrid, Spain
• HER past: Looking back on two decades of HER2-targeted therapy
  Eva Ciruelos, Madrid, Spain, Fatima Cardoso, Lisbon, Portugal
• HER new potential: New advances in HER2+ breast cancer treatment
  Erika Hamilton, Nashville, United States
• Sharing HER experience: Case-based panel discussion
  Eva Ciruelos, Madrid, Spain, Erika Hamilton, Nashville, United States, Karen Gelmon, Vancouver, Canada, Fatima Cardoso, Lisbon, Portugal
• Closing remarks
  Eva Ciruelos, Madrid, Spain

The complete picture: Managing breast cancer in the real-world
Pfizer Oncology

• Setting the scene: The evolution of breast cancer care
  Antonio Llombart Cussac, Lleida, Spain
• Framing the shot: Examining current practice in HR+/HER2- aBC
  Adam Brufsky, Pittsburgh, United States
• Changing perspectives: Exploring the patient focus in HR+/HER2- aBC
  Adam Brufsky, Pittsburgh, United States
• Views from the clinic: Challenges, choices, and confidence when treating your patients with germline BRCA-mutated HER2- LA or mBC
  Suzette Delaloge, Paris, France
• New perspectives: Looking to the future of breast cancer care
  Antonio Llombart Cussac, Lleida, Spain
• Live Q&A
  Antonio Llombart Cussac, Lleida, Spain

Transforming patient care: Leveraging the latest clinical data in HER2-positive eBC
F. Hoffmann-La Roche

• Welcome and Introduction: Evolution of patient care in HER2-positive eBC
  Eva Ciruelos, Madrid, Spain
• How to ensure optimal treatment for patients with residual disease
  Andrew Wardley, Manchester, United Kingdom
• Continuing a patient's journey after pCR: Evidence-based decision–making
  Christian Jackisch, Offenbach am Main, Germany
• Panel discussion
  Eva Ciruelos, Madrid, Spain, Christian Jackisch, Offenbach am Main, Germany, Andrew Wardley, Manchester, United Kingdom
• Summary and close
  Eva Ciruelos, Madrid, Spain
• Live Q&A
  Eva Ciruelos, Madrid, Spain

GASTROINTESTINAL TUMOURS

Can current treatment strategies for mCRC be further optimized?
Servier

• Introduction
  Fortunato Ciardiello, Napoli, Italy
• Optimizing treatment strategies in the first-line mCRC
  Thierry André, Paris, France, Mark Saunders, Manchester, United Kingdom
• Extending the continuum of care beyond the second-line mCRC
  Per Pfeiffer, Odense, Denmark, Timothy Price, Woodville, Australia
• Conclusion
  Fortunato Ciardiello, Napoli, Italy
• Live Q&A
  Fortunato Ciardiello, Napoli, Italy

Current status and future directions for immunotherapy in hepatocellular carcinoma
AstraZeneca

• Current status and future directions for immunotherapy in hepatocellular carcinoma
  Ghassan Abou-Alfa, New York, United States, Bruno Sangro, Pamplona, Spain, Peter R. Galle, Mainz, Germany

Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
F. Hoffmann-La Roche

• Welcome and introductions
  Arndt Vogel, Hannover, Germany
• Tracking the recent advances within the field of unresectable HCC
  David Pinato, London, United Kingdom
• Reviewing the latest phase III efficacy data for unresectable HCC
  Andrew Zhu, Boston, United States
• Exploring key safety data for cancer immunotherapy combinations
  Philippe Merle, Lyon, France
• Moving into the clinic: how will these data inform our clinical decisions?
  Arndt Vogel, Hannover, Germany
• Panel discussion
  Arndt Vogel, Hannover, Germany, David Pinato, London, United Kingdom, Philippe Merle, Lyon, France, Andrew Zhu, Boston, United States
• Live Q&A
  Arndt Vogel, Hannover, Germany

Joining efforts beyond first-line management in patients with metastatic pancreatic cancer
Servier

• Welcome and introduction
  Gerald Prager, Vienna, Austria
• Tumor Registry Pancreatic Cancer: A national registry for the evaluation of treatment strategies in pancreatic cancer
  Norbert Marschner, Freiburg im Breisgau, Germany
• Joining efforts across the borders in improving mPDAC patient outcomes
  Gerald Prager, Vienna, Austria, Junji Furuse, Tokyo, Japan
• Exploring new treatment strategies to improve outcomes for patients with metastatic pancreatic cancer
  Cindy Neuzillet, Clichy, France
• Conclusion
  Gerald Prager, Vienna, Austria
• Live Q&A
  Gerald Prager, Vienna, Austria

The future is now: Transforming management of GI cancer with immuno-oncology
Bristol Myers Squibb

• The future is now: Transforming management of GI cancer with immuno-oncology
  Markus Möhler, Mainz, Germany, Sara Lonardi, Padova, Italy, Elizabeth Smyth, Cambridge, United Kingdom

The today and tomorrow of systemic treatment for HCC
Ipsen

• Welcome and introductions
  Peter R. Galle, Mainz, Germany
• Understanding the current landscape: Insights from clinical practice
  Thomas Yau, Hong Kong, China
• How data could shape the future of clinical practice
  Lorenza Rimassa, Rozzano, Italy
• Close
  Peter R. Galle, Mainz, Germany
• Live Q&A
  Peter R. Galle, Mainz, Germany, Thomas Yau, Hong Kong, China, Lorenza Rimassa, Rozzano, Italy

GENITOURINARY TUMOURS (NON-PROSTATE)

Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRcc
Bristol Myers Squibb

• Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach
  James Larkin, London, United Kingdom, Nizar Tannir, Houston, United States, Michael Atkins, Washington DC, United States

Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche

• Welcome and introduction
  Karim Fizazi, Villejuif, France
• Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
  Enrique Grande, Madrid, Spain
• The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
  Karim Fizazi, Villejuif, France
• Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
  Johann de Bono, London, United Kingdom
• Live Q&A
  Karim Fizazi, Villejuif, France

What does the changing treatment landscape for aRCC mean for patient care: An expert discussion
Ipsen

• Welcome and introduction
  Cristina Suarez, Barcelona, Spain
• Shifting perceptions in the first-line treatment of aRCC
  Toni Choueiri, Boston, United States
• Personalizing treatment approaches in clinical practice. Part 1: Sequencing of treatment in aRCC following progression
  Camillo Guglielmo Porta, Pavia, Italy
• Personalizing treatment approaches in clinical practice. Part 2: Understanding the patient experience of aRCC
  Howard Gurney, Sydney, Australia
• Closing comments
  Cristina Suarez, Barcelona, Spain
• Live Q&A
  Cristina Suarez, Barcelona, Spain

GENITOURINARY TUMOURS (PROSTATE)

Advanced prostate cancer: How do we move forward in patient management?
Janssen

• Optimising care for individual patients with metastatic hormone sensitive prostate cancer
  Eleni Efstathiou, Houston, United States, Elena Castro, Madrid, Spain, Nicolas Mottet, Saint-Etienne, France, Kim Chi, Vancouver, Canada, Boris Hadaschik, Essen, Germany
• Non metastatic castration resistant prostate cancer translating benefit to clinical practice & Choosing the right pathway in the current and future management of metastatic castration resistant prostate cancer
  Boris Hadaschik, Essen, Germany, Kim Chi, Vancouver, Canada, Elena Castro, Madrid, Spain, Eleni Efstathiou, Houston, United States, Nicolas Mottet, Saint-Etienne, France
• Flattening the curve: Consequences for the management of prostate cancer in the ongoing COVID-19 pandemic
  Eleni Efstathiou, Houston, United States, Boris Hadaschik, Essen, Germany, Nicolas Mottet, Saint-Etienne, France, Kim Chi, Vancouver, Canada, Elena Castro, Madrid, Spain
• Live Q&A
  Eleni Efstathiou, Houston, United States, Nicolas Mottet, Saint-Etienne, France, Boris Hadaschik, Essen, Germany, Elena Castro, Madrid, Spain, Kim Chi, Vancouver, Canada

Building a new paradigm in prostate cancer
Pfizer Oncology

• Challenges in the treatment of prostate cancer
  Daniel George, Durham, United States
• Maximizing outcome with NHTs
  Arnulf Stenzl, Tuebingen, Germany
• Expanding the potential of PARP inhibitors
  Joaquin Mateo, Barcelona, Spain
• Summary
  Daniel George, Durham, United States
• Live Q&A
  Daniel George, Durham, United States, Joaquin Mateo, Barcelona, Spain, Arnulf Stenzl, Tuebingen, Germany

Extending overall survival in nmCRPC while maintaining quality of life: Can we have it all?
PeerVoice

• Welcome and introduction
  Neal Shore, Myrtle Beach, United States
• Overall Survival in nmCRPC: Translating Recent Data Into a Plan of Action
  Neal Shore, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Gero Kramer, Vienna, Austria, Jennifer Sutton, Myrtle Beach, United States
• Mitigating and managing adverse events associated with androgen receptor-targeted therapies
  Neal Shore, Myrtle Beach, United States, Jennifer Sutton, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Gero Kramer, Vienna, Austria
• Quality of life as a therapeutic goal for nmCRPC
  Neal Shore, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Jennifer Sutton, Myrtle Beach, United States, Gero Kramer, Vienna, Austria
• Case studies in nmCRPC: Applying knowledge to practice
  Neal Shore, Myrtle Beach, United States, Gero Kramer, Vienna, Austria, Jennifer Sutton, Myrtle Beach, United States, Karim Fizazi, Villejuif, France
• Faculty Q&A and Take-Home Messages
  Neal Shore, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Gero Kramer, Vienna, Austria, Jennifer Sutton, Myrtle Beach, United States

PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
AstraZeneca

• Chair’s welcome and introductions
  Neal Shore, Myrtle Beach, United States
• Exploring molecular heterogeneity in prostate cancer - prevalence and clinical significance
  Neal Shore, Myrtle Beach, United States
• Dissecting the clinical data for PARP inhibitors in metastatic castrate resistant prostate cancer
  Joaquin Mateo, Barcelona, Spain
• Considerations for the approach to HRRm testing in prostate cancer
  Alexander Wyatt, Vancouver, Canada
• Panel discussion
  Neal Shore, Myrtle Beach, United States, Joaquin Mateo, Barcelona, Spain, Alexander Wyatt, Vancouver, Canada
• Summary and meeting close
  Neal Shore, Myrtle Beach, United States

Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche

• Welcome and introduction
  Karim Fizazi, Villejuif, France
• Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
  Enrique Grande, Madrid, Spain
• The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
  Karim Fizazi, Villejuif, France
• Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
  Johann de Bono, London, United Kingdom

GYNECOLOGICAL TUMOURS

Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
AstraZeneca

• Chair’s welcome and introductions
  Ana Oaknin, Barcelona, Spain
• Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer
  Thomas Herzog, Cincinnati, United States
• Broadening horizons: new data and combinations with PARP inhibitors
  Isabelle Ray-Coquard, Lyon, France
• Optimising clinical outcomes: the case for personalised medicine in ovarian cancer
  Ignace Vergote, Leuven, Belgium
• Panel discussion
  Ana Oaknin, Barcelona, Spain, Isabelle Ray-Coquard, Lyon, France, Thomas Herzog, Cincinnati, United States, Ignace Vergote, Leuven, Belgium
• Summary and meeting close
  Ana Oaknin, Barcelona, Spain

Treatment options for women with advanced ovarian cancer: Evaluating the evidence
GSK

• Chairs` Introduction
  Antonio González Martín, Madrid, Spain, Bradley Monk, Phoenix, United States
• Predictors of treatment outcomes in patients with advanced ovarian cancer
  Bradley Monk, Phoenix, United States
• Evaluating first-line maintenance therapy options
  Antonio González Martín, Madrid, Spain
• The role of genetic testing in the treatment decision-making process
  Kathleen Moore, Oklahoma City, United States
• PARPi in the treatment of recurrent disease
  Jonathan Ledermann, London, United Kingdom
• Live Q&A
  Bradley Monk, Phoenix, United States

Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
GSK

• Welcome and Introduction
  Robert Coleman, The Woodlands, United States, Robert Coleman, The Woodlands, United States
• Evolution of diagnosis and classification of endometrial cancer and emergence of molecular classification
  Amit Oza, Toronto, Canada
• Endometrial cancer as an attractive target for checkpoint inhibitor-based therapy
  Robert Coleman, The Woodlands, United States
• Monotherapy checkpoint inhibitor studies in recurrent endometrial cancer
  Renaud Sabatier, Marseille, Cedex 09, France
• Combination checkpoint inhibitor studies in newly diagnosed and recurrent endometrial cancer
  Ana Oaknin, Barcelona, Spain
• Patient journeys of 2 women with recurrent/advanced EC
  Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States
• Conclusion
  Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States
• Live Q&A
  Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States

IMMUNO-ONCOLOGY

Antibody Drug Conjugates (ADCs): Advancements in the treatment of solid tumours
Daiichi Sankyo

• Welcome and introduction
  Pasi Jänne, Boston, United States
• ADCs as a technologically advanced treatment approach in solid tumours
  Pasi Jänne, Boston, United States
• Current clinical experience with innovative ADCs in breast cancer
  Javier Cortés, Barcelona, Spain
• Latest findings from clinical trials in lung cancer with technologically advanced ADCs
  Pasi Jänne, Boston, United States
• Recent clinical findings with novel ADCs in colorectal and gastric cancer
  Kanwal Raghav, Houston, United States
• Summary and close
  Pasi Jänne, Boston, United States
• Live Q&A
  Pasi Jänne, Boston, United States

Current status and future directions for immunotherapy in hepatocellular carcinoma
AstraZeneca

• Current status and future directions for immunotherapy in hepatocellular carcinoma
  Ghassan Abou-Alfa, New York, United States, Bruno Sangro, Pamplona, Spain, Peter R. Galle, Mainz, German

Exploring the Current and Evolving Landscape in Thoracic Cancers
Bristol Myers Squibb

• Exploring the current and evolving landscape in thoracic cancers
  Martin Reck, Grosshansdorf, Germany, Paul Baas, Amsterdam, Netherlands, Tina Cascone, Houston, United States
• Live Q&A
  Martin Reck, Grosshansdorf, Germany, Tina Cascone, Houston, United States, Paul Baas, Amsterdam, Netherlands

Immune checkpoint blockade in non-melanoma skin cancer
Sanofi Genzyme

• Welcome introduction and objectives and Treatment for locally advanced/metastatic cutaneous squamous cell carcinoma (CSCC)
  Chrysalyne Schmults, Harvard, United States
• Exploring the emerging research with immuno-oncology in CSCC
  Dirk Schadendorf, Essen, Germany
• Emerging research with immune checkpoint inhibitors in basal cell carcinoma (BCC)
  Susana Puig, Barcelona, Spain

Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
F. Hoffmann-La Roche

• Welcome and introductions
  Arndt Vogel, Hannover, Germany
• Tracking the recent advances within the field of unresectable HCC
  David Pinato, London, United Kingdom
• Reviewing the latest phase III efficacy data for unresectable HCC
  Andrew Zhu, Boston, United States
• Exploring key safety data for cancer immunotherapy combinations
  Philippe Merle, Lyon, France
• Moving into the clinic: how will these data inform our clinical decisions?
  Arndt Vogel, Hannover, Germany
• Panel discussion
  Arndt Vogel, Hannover, Germany, David Pinato, London, United Kingdom, Philippe Merle, Lyon, France, Andrew Zhu, Boston, United States
• Live Q&A
  Arndt Vogel, Hannover, Germany

Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

F. Hoffmann-La Roche

• Welcome and introduction
  Karim Fizazi, Villejuif, France
• Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
  Enrique Grande, Madrid, Spain
• The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
  Karim Fizazi, Villejuif, France
• Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
  Johann de Bono, London, United Kingdom
• Live Q&A
  Karim Fizazi, Villejuif, France

The future is now: Transforming management of GI cancer with immuno-oncology

Bristol Myers Squibb

• The future is now: Transforming management of GI cancer with immuno-oncology
  Markus Möhler, Mainz, Germany, Sara Lonardi, Padova, Italy, Elizabeth Smyth, Cambridge, United Kingdom

Update on the evolving landscape for endometrial cancer treatment with Immunotherapy

GSK

• Welcome and Introduction
  Robert Coleman, The Woodlands, United States, Robert Coleman, The Woodlands, United States
• Evolution of diagnosis and classification of endometrial cancer and emergence of molecular classification
  Amit Oza, Toronto, Canada
• Endometrial cancer as an attractive target for checkpoint inhibitor-based therapy
  Robert Coleman, The Woodlands, United States
• Monotherapy checkpoint inhibitor studies in recurrent endometrial cancer
  Renaud Sabatier, Marseille, Cedex 09, France
• Combination checkpoint inhibitor studies in newly diagnosed and recurrent endometrial cancer
  Ana Oaknin, Barcelona, Spain
• Patient journeys of 2 women with recurrent/advanced EC
  Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States
• Conclusion
  Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States
• Live Q&A
  Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States

LUNG CANCER

Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Janssen

• An overview of NSCLC
  Pilar Garrido, Madrid, Spain, Marina Garassino, Milan, Italy
• Uncommon EGFR mutations in NSCLC
  Matthew Krebs, Manchester, United Kingdom, Zosia Piotrowska, Boston, United States
• Looking to the future: How can emerging therapeutic options influence the management landscape
  Lecia Sequist, Boston, United States, Benjamin Besse, Villejuif, France
• Live Q&A
  Pilar Garrido, Madrid, Spain, Matthew Krebs, Manchester, United Kingdom, Lecia Sequist, Boston, United States

Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Pfizer Oncology

• Welcome and introduction
  Rosario Garcia Campelo, A Coruña, Spain
• Latest updates in molecular testing in NSCLC
  Justin Gainor, Boston, United States
• EGFR+ NSCLC: A personalised sequencing approach
  Jesus Corral Jaime, Pamplona, Spain
• ALK+ and ROS1+ NSCLC: Optimising patient outcomes
  Todd Bauer, Nashville, United States

Treatment Options for Non-Small Cell Lung Cancer
Boehringer Ingelheim

• Welcome and introduction
  Tanja Čufer, Golnik, Slovenia
• Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma
  Silvia Novello, Turin, Italy
• Uncommon EGFR Mutations
  Xiuning Le, Houston, United States
• The Future of NSCLC
  Melissa Johnson, Nashville, United States
• Key insights and closing remarks
  Tanja Čufer, Golnik, Slovenia
• Live Q&A
  Tanjia Čufer, Golnik, Slovenia, Xiuning Le, Houston, United States, Melissa Johnson, Nashville, United States, Silvia Novello, Turin, Italy

Evolving strategies: Managing treatment of early stage and advanced lung cancers
AstraZeneca

• Welcome and Introduction
  David Spigel, Nashville, United States
• Extensive-stage SCLC: Changing the paradigm with immune-oncology combinations
  David Spigel, Nashville, United States
• Unresectable stage III NSCLC: Clinical advances in the implementation of immuno-oncology therapy
  Johan Vansteenkiste, Leuven, Belgium
• Early stage EGFRm NSCLC: Targeted treatment options following complete surgical resection
  Tom John, Heidelberg, Australia
• Locally advanced or metastatic EGFRm NSCLC: Targeted treatment options to improve outcomes in the first-line setting and beyond progression
  David Planchard, Villejuif, France

Exploring the Current and Evolving Landscape in Thoracic Cancers
Bristol Myers Squibb

• Exploring the current and evolving landscape in thoracic cancers
  Martin Reck, Grosshansdorf, Germany, Paul Baas, Amsterdam, Netherlands, Tina Cascone, Houston, United States
• Live Q&A
  Martin Reck, Grosshansdorf, Germany, Tina Cascone, Houston, United States, Paul Baas, Amsterdam, Netherland

MELANOMA AND OTHER SKIN CANCERS

Immune checkpoint blockade in non-melanoma skin cancer
Sanofi Genzyme

• Welcome introduction and objectives and Treatment for locally advanced/metastatic cutaneous squamous cell carcinoma (CSCC)
  Chrysalyne Schmults, Harvard, United States
• Exploring the emerging research with immuno-oncology in CSCC
  Dirk Schadendorf, Essen, Germany
• Emerging research with immune checkpoint inhibitors in basal cell carcinoma (BCC)
  Susana Puig, Barcelona, Spain

Melanoma in 2020: Reflect, reset, and continue
Bristol Myers Squibb

• Melanoma in 2020: Reflect, reset, and continue
  James Larkin, London, United Kingdom, Pippa Corrie, Cambridge, United Kingdom, Paolo Ascierto, Naples, Italy

PRECISION MEDICINE

NGS Biomarker testing: Time matters . No longer need to wait for weeks, as this can now happen within days
Thermo Fisher Scientific

• Introduction
  L. Quagliata (Basel, Switzerland)
• Genomic profiling is driving the precision oncology
  P. Jermann (Basel, Switzerland)
• Lung cancer diagnostic test needs: perspective from a thoracic oncologist
  G. Fernandes (Porto, Portugal)
• Establishment of a large-scale Asian genomic screening platform to identify non-small cell lung cancer with rare driver oncogenes and clarify drug resistant mechanisms
  K. Goto (Kashiwa, Japan)
• NTRK, RET and other fusion biomarkers testing: Latest developments
  P. Jermann (Basel, Switzerland)

Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team

Bayer

• Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
  Jean-Yves Blay, Lyon, France, Jesus Garciafoncillas, Madrid, Spain, Gilad Vainer, Jerusalem, Israel, Maximilian Hochmair, Vienna, Austria, Marcia Simpson Brose,Philadelphia, United States

Putting personalised healthcare at the heart of clinical practice
F. Hoffmann-La Roche

• Taking the pulse of personalised healthcare today
  Emile Voest, Amsterdam, Netherlands
• Tracing our path with current tools
  Shumei Kato, San Diego, United States
• If tissue is the issue, think blood
  Natalie Cook, Manchester, United Kingdom
• Learning from real-world patients, in real-life conditions
  Kenneth Kehl, Boston, United States
• Looking at where personalised healthcare has become reality
  Emile Voest, Amsterdam, Netherlands
• Conclusion
  Emile Voest, Amsterdam, Netherlands
• Live Q&A
  Emile Voest, Amsterdam, Netherlands

REAL WORLD EVIDENCE / MULTIDISCIPLINARY

Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Bayer

• Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
  Jean-Yves Blay, Lyon, France, Jesus Garciafoncillas, Madrid, Spain, Gilad Vainer, Jerusalem, Israel, Maximilian Hochmair, Vienna, Austria, Marcia Simpson Brose,Philadelphia, United States

RWE and me: Multidisciplinary views on real-world evidence (RWE) in oncology
Pfizer Oncology

• Welcome and introduction
  George Demetri, Boston, United States
• The patient perspective: The relevance of RWE in patient decision-making
  Renate Haidinger, Hohenbrunn, Germany
• The physician perspective: Using RWE to inform clinical decisions in day-to-day practice and drug discovery
  George Demetri, Boston, United States
• The regulator perspective: RWE and real-world data (RWD) in drug approvals and label expansions
  Jorge Camarero, Madrid, Spain
• The payer perspective: Utilising RWD to determine the value of drugs
  Oriol Solà-Morales, Sant Cugat del Valles, Spain
• Panel discussion
  George Demetri, Boston, United States, Jorge Camarero, Madrid, Spain, Oriol Solà-Morales, Sant Cugat del Valles, Spain, Renate Haidinger, Hohenbrunn, Germany
• Live Q&A
  George Demetri, Boston, United States

The complete picture: Managing breast cancer in the real-world
Pfizer Oncology

• Setting the scene: The evolution of breast cancer care
  Antonio Llombart Cussac, Lleida, Spain
• Framing the shot: Examining current practice in HR+/HER2- aBC
  Adam Brufsky, Pittsburgh, United States
• Changing perspectives: Exploring the patient focus in HR+/HER2- aBC
  Adam Brufsky, Pittsburgh, United States
• Views from the clinic: Challenges, choices, and confidence when treating your patients with germline BRCA-mutated HER2- LA or mBC
  Suzette Delaloge, Paris, France
• New perspectives: Looking to the future of breast cancer care
  Antonio Llombart Cussac, Lleida, Spain
• Live Q&A
  Antonio Llombart Cussac, Lleida, Spain